U.S. Markets close in 3 hrs 21 mins
  • S&P 500

    -0.28 (-0.01%)
  • Dow 30

    -69.29 (-0.19%)
  • Nasdaq

    +38.12 (+0.24%)
  • Russell 2000

    +20.50 (+0.91%)
  • Crude Oil

    +0.42 (+0.58%)
  • Gold

    -0.50 (-0.03%)
  • Silver

    -0.10 (-0.44%)

    +0.0078 (+0.6924%)
  • 10-Yr Bond

    +0.0430 (+2.91%)
  • Vix

    -0.94 (-4.29%)

    -0.0001 (-0.0093%)

    +0.1500 (+0.1321%)

    -619.82 (-1.22%)
  • CMC Crypto 200

    +7.08 (+0.54%)
  • FTSE 100

    -2.55 (-0.03%)
  • Nikkei 225

    +405.02 (+1.42%)

Paul Touhey Named Executive Chairman at Invisible Sentinel

PHILADELPHIA, PA--(Marketwired - May 21, 2013) - Invisible Sentinel Inc., a life-sciences company that develops rapid diagnostics for the detection of foodborne pathogens, announced that Paul Touhey, formerly President and Chief Executive Officer of Fujirebio Diagnostics, has been appointed Executive Chairman.

Touhey brings more than 25 years of accomplishment in the diagnostics industry to Invisible Sentinel's management team. During his 10-year tenure as the President and CEO of Fujirebio Diagnostics, the company became the worldwide leader for cancer-diagnostics. He was appointed to the Board of Invisible Sentinel in October 2012.

"Having already benefited from Paul's experience since he joined our Board, we look forward to the contributions he will now make as a member of our management team," said Nick Siciliano, co-founder of Invisible Sentinel. "His appointment comes during a period of expansion for our company as we commercialize our suite of first-in-class Veriflow™ diagnostic assays for the food industry. We anticipate our second product approval in the weeks to come, and we are developing others to follow it."

Invisible Sentinel has pending before the Association of Analytical Communities (AOAC) an application for accreditation of the Company's diagnostic for the detection of Listeria monocytogenes, a bacterium that is one of the most virulent food-born pathogens. The AOAC validates analytical test methods for the food industry.

Invisible Sentinel's diagnostic for the detection of Campylobacter jejuni and Campylobacter coli in poultry received AOAC accreditation last October. The product was the first hand-held molecular diagnostic to be approved by the AOAC for the detection of foodborne pathogens.

Touhey began his career at Johnson & Johnson, where he held positions of increasing responsibility before joining Centocor Diagnostics, a unit of Centocor, Inc., in 1985. At Centocor Diagnostics he served as Vice President of Operations as the company took a pioneering role in developing novel diagnostics from monocloncal antibodies. Fujirebio acquired Centocor Diagnostics in 1998. In addition to his position as President and CEO at Fujirebio Diagnostics, Touhey served as a member of the Board of Directors for both Fujirebio Diagnostics and its parent company, Fujirebio Inc.

Touhey is the past Chairman and a current member of the Board of the Medical Device Manufacturers Association, a national trade association representing the entrepreneurial sector of the medical-device industry in the United States, and a member of the Board of Pennsylvania Bio, the trade association of the life-sciences industry in Pennsylvania. In 2010, he was named CEO of the Year by Pennsylvania Bio for his leadership in the bioscience community.

Touhey established the Companies of Caring Campaign with the Community Volunteers in Medicine, a Chester County charity focusing on providing medical care to the uninsured, and was formerly a member of the Freedom Valley YMCA Board of Directors.

Touhey also previously served on the Board of Directors of Orthovita, Inc., an orthobiologics company, and Cernostics, a cancer-diagnostics company. Touhey currently serves on the Board of Directors of Tela Bio, Inc., an orthopedics company. He also continues to serve as an advisor to Fujirebio Diagnostics.

About Invisible Sentinel
Based in Philadelphia at the University City Science Center, Invisible Sentinel develops diagnostic technologies for a safer food supply. The Company's focus is on developing rapid diagnostics that quickly provide accurate information about the presence of harmful pathogens. The first-in-class patented technology, produced under good manufacturing practices, provides the same data as the US Department of Agriculture reference methods but minimizes the time, reduces the cost, and lowers the overhead associated with conventional diagnostics. The food industry is the first market that the Company is targeting, but its platform technology has the potential to provide valuable tools for additional industries including healthcare, veterinary, biodefense, and environmental testing, where rapid detection of target analytes from unrefined samples is critical. Uniquely designed for easy, practical use -- on-site and throughout the entire food distribution network -- Invisible Sentinel's proprietary diagnostic products promise to create a new standard for rigorous quality control.

About the University City Science Center
The University City Science Center accelerates technology commercialization, regional economic development, and the market availability of life-enhancing scientific breakthroughs by bringing together innovations, scientists, entrepreneurs, funding, laboratory facilities, and business services. Established in 1963 and headquartered in Philadelphia, PA, the Science Center was the first, and remains the largest, urban research park in the United States. Graduate organizations and current residents of the University City Science Center's Port Business Incubators have created more than 15,000 jobs that remain in the Greater Philadelphia region today and contribute more than $9 billion to the regional economy annually. For more information about the Science Center, go to www.sciencecenter.org.